Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

2.870
-0.120-4.01%
Volume:34.03M
Turnover:98.59M
Market Cap:11.47B
PE:15.72
High:3.030
Open:3.000
Low:2.860
Close:2.990
52wk High:4.490
52wk Low:1.790
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:0.91
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.183
ROE:4.14%
ROA:2.41%
PB:0.62
PE(LYR):15.72
PS:1.58

Loading ...

Luye Pharma Enrolls First Patient in Phase 2 China Trial of Alzheimer's Psychosis Drug

MT Newswires Live
·
Yesterday

CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion

Stock News
·
Yesterday

LUYE PHARMA's Innovative Drug LY03017 Enrolls First Patient in Chinese Phase II Trial for Alzheimer's Disease Psychosis

Stock News
·
Apr 15

Luye Pharma initiates China Phase II trial of LY03017 targeting Alzheimer’s disease-related psychosis

Bulletin Express
·
Apr 15

A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia

Simply Wall St.
·
Apr 15

LUYE PHARMA Shares Climb Nearly 3% in Morning Session as Self-Developed Drug LY03020 Enrolls First Patient in Chinese Phase II Trial

Stock News
·
Apr 14

UBS Increases Stake in LUYE PHARMA by 13.95 Million Shares at HK$2.85 Each

Stock News
·
Apr 13

LUYE PHARMA's Innovative Drug LY03020 Enrolls First Patient in Chinese Phase II Trial

Stock News
·
Apr 08

Luye Pharma enrolls first patient in China Phase II trial of LY03020 schizophrenia drug

Reuters
·
Apr 08

Luye Pharma Maintains Stable Share Base in March 2026; USD 180 Million Convertible Bonds Allow Up to 288.79 Million New Shares

Bulletin Express
·
Apr 08

Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks

Simply Wall St.
·
Apr 06

Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision

Simply Wall St.
·
Apr 04

Stock Track | LUYE PHARMA Stock Soars 5.17% in Intraday Trading After Reporting Strong 2025 Profit Growth

Stock Track
·
Apr 02

LUYE PHARMA Shares Surge Nearly 5% on Strong 2025 Profit Growth

Stock News
·
Apr 02

Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%

MT Newswires Live
·
Mar 31

BRIEF-Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN

Reuters
·
Mar 31

Luye Pharma 2025 Net Profit Up 9.4% to RMB705.70 Million as Oncology and CNS Sales Accelerate

Bulletin Express
·
Mar 31

Luye Pharma Group FY Net Income Attributable RMB 618.7 Million

THOMSON REUTERS
·
Mar 31

Luye Pharma Group FY Revenue RMB 6,308.4 Million

THOMSON REUTERS
·
Mar 31

Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million

Reuters
·
Mar 30